Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$4000.0.

  • Lineage Cell Therapeutics' Exchange Rate Effect fell 11052.63% to -$4000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $241000.0, marking a year-over-year increase of 4876.54%. This contributed to the annual value of -$95000.0 for FY2024, which is 6200.0% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Exchange Rate Effect stood at -$4000.0, which was down 11052.63% from $293000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Exchange Rate Effect registered a high of $293000.0 during Q2 2025, and its lowest value of -$634000.0 during Q3 2022.
  • Its 5-year average for Exchange Rate Effect is -$53789.5, with a median of -$70000.0 in 2024.
  • In the last 5 years, Lineage Cell Therapeutics' Exchange Rate Effect tumbled by 714444.44% in 2022 and then surged by 46153.85% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Exchange Rate Effect (Quarter) stood at $14000.0 in 2021, then plummeted by 657.14% to -$78000.0 in 2022, then soared by 461.54% to $282000.0 in 2023, then tumbled by 91.13% to $25000.0 in 2024, then crashed by 116.0% to -$4000.0 in 2025.
  • Its last three reported values are -$4000.0 in Q3 2025, $293000.0 for Q2 2025, and -$73000.0 during Q1 2025.